Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency

The stability of mRNA lipid nanoparticles (LNPs) is crucial for their effectiveness in delivering genetic material, and ultimately, for the success of treatments like COVID-19 vaccines. However, the vulnerability of these nanoparticles to freezing temperatures poses significant challenges for their storage and transportation. This issue is particularly pressing given the global distribution of mRNA-based vaccines and therapies, which requires maintaining their potency across various environmental conditions.

The research collaboration between The University of Texas at Austin and Eli Lilly and Company sheds light on the impact of storage conditions on mRNA LNPs and identifies Tris buffer as a key component in helping these nanoparticles retain their potency even after freezing. This finding has important implications for the pharmaceutical industry, as it could simplify the storage and handling of mRNA-based treatments, making them more accessible and reliable. The use of Tris buffer could be a straightforward yet effective solution to mitigate the freezing-related degradation of mRNA LNPs.

As the demand for mRNA-based therapies continues to grow, understanding the factors that influence their stability and potency is essential. The next step is to see how this research translates into real-world applications, particularly in the development and distribution of future mRNA-based treatments. It will be crucial to monitor further studies that investigate the long-term effects of using Tris buffer in mRNA LNPs and how this approach compares to other methods for preserving their potency.

Originally reported by phys.org. NewsData adds analysis for science & discovery readers.